The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
Ability and willingness to comply with the requirements of the study protocol
Age ≥18 years
Diagnosis of the following histories according to the WHO criteria
CLL or SLL
Known active histological transformation from CLL to an aggressive lymphoma (i.e., Richter"s transformation)
Active malignancy or systemic therapy for another malignancy within 3 years; local/regional therapy with curative intent such as surgical resection or localized radiation within 3 years of treatment is permitted
Other diagnosis of active cancer
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1
Memorial Sloan Kettering Cancer Center
Lead sponsor
Roche-Genentech
Collaborator
Massachusetts General Hospital
Collaborator
BeOne Medicines
Collaborator